UK markets open in 5 hours 40 minutes

Genmab A/S (0MGB.L)

LSE - LSE Delayed price. Currency in DKK
Add to watchlist
2,581.26-9.88 (-0.38%)
At close: 05:18PM GMT

Genmab A/S

Kalvebod Brygge 43
Copenhagen 1560
Denmark
45 70 20 27 28
https://www.genmab.com

Sector(s)
Industry
Full-time employees2,132

Key executives

NameTitlePayExercisedYear born
Dr. Jan G.J. van de Winkel Ph.D.Co-Founder, President & CEO18.8MN/A1961
Mr. Anthony PaganoExecutive VP & CFO7MN/A1978
Mr. Anthony ManciniExecutive VP & COO7.6MN/A1971
Mr. Martin SchultzSenior Director of Clinical Operations & Non-Independent Director500kN/A1976
Dr. Judith V. Klimovsky M.D.Executive VP & Chief Development Officer7.9MN/A1958
Dr. Tahamtan AhmadiExecutive VP, Chief Medical Officer & Head of Experimental Medicines7.5MN/A1973
Dr. Mijke Zachariasse Ph.D.Senior Director, Head of Antibody Research Materials & Non-Independent Director1MN/A1974
Mr. Takahiro HamataniSenior Director of Finance Japan & Non-Independent Director500kN/A1975
Mr. Andrew CarlsenSenior Director, VP & Head of Investor RelationsN/AN/AN/A
Ms. Birgitte Stephensen M.Sc.Executive VP & Chief Legal OfficerN/AN/A1961
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in DKK.

Description

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company also develops Teclistamab, which is in Phase 2 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Corporate governance

Genmab A/S’s ISS governance QualityScore as of 1 December 2023 is 3. The pillar scores are Audit: 2; Board: 1; Shareholder rights: 1; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.